| Literature DB >> 35061862 |
Yuki Nagakubo1,2,3, Yosuke Hirotsu1, Makoto Maejima2, Masahiro Shibusawa2, Kazuhiro Hosaka2, Kenji Amemiya3, Hitomi Sueki2, Miyoko Hayakawa4, Hitoshi Mochizuki1,4,5, Toshiharu Tsutsui6, Yumiko Kakizaki6, Yoshihiro Miyashita6, Masao Omata5,7.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has circulated worldwide and causes coronavirus disease 2019 (COVID-19). At the onset of the COVID-19 pandemic, infection control measures were taken, such as hand washing, mask wearing, and behavioral restrictions. However, it is not fully clear how the effects of these non-pharmaceutical interventions changed the prevalence of other pathogens associated with respiratory infections. In this study, we collected 3,508 nasopharyngeal swab samples from 3,249 patients who visited the Yamanashi Central Hospital in Japan from March 1, 2020 to February 28, 2021. We performed multiplex polymerase chain reaction (PCR) using the FilmArray Respiratory Panel and singleplex quantitative reverse transcription PCR targeting SARS-CoV-2 to detect respiratory disease-associated pathogens. At least one pathogen was detected in 246 (7.0%) of the 3,508 samples. Eleven types of pathogens were detected in the samples collected from March-May 2020, during which non-pharmaceutical interventions were not well implemented. In contrast, after non-pharmaceutical interventions were thoroughly implemented, only five types of pathogens were detected, and the majority were SARS-CoV-2, adenoviruses, or human rhinoviruses / enteroviruses. The 0-9 year age group had a higher prevalence of infection with adenoviruses and human rhinoviruses / enteroviruses compared with those 10 years and older, while those 10 years and older had a higher prevalence of infection with SARS-CoV-2 and other pathogens. These results indicated that non-pharmaceutical interventions likely reduced the diversity of circulating pathogens. Moreover, differences in the prevalence of pathogens were observed among the different age groups.Entities:
Mesh:
Year: 2022 PMID: 35061862 PMCID: PMC8782330 DOI: 10.1371/journal.pone.0262874
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Age distribution of the 3,508 samples.
| Age (year) | Number of samples | (%) |
|---|---|---|
| 0–9 | 268 | 7.7 |
| 10–19 | 133 | 3.8 |
| 20–29 | 282 | 8.1 |
| 30–39 | 219 | 6.3 |
| 40–49 | 261 | 7.5 |
| 50–59 | 310 | 8.9 |
| 60–69 | 376 | 10.7 |
| 70–79 | 703 | 20.1 |
| 80–89 | 701 | 20.0 |
| 90–99 | 247 | 7.1 |
| ≥100 | 8 | 0.2 |
|
|
|
|
Fig 1Trends in the circulation of SARS-CoV-2 and other respiratory pathogens during the COVID-19 pandemic.
Fig 2Detection frequency of each pathogen.
Fig 3Respiratory-related pathogen infections by age group.
(A) Number of positive samples in each age group. Bar plots indicate samples in which at least one pathogen was detected (pink) and samples in which none were detected (light blue). (B) Percentage of positive samples in each age group. The graph shows the number of positive samples detected in each age group divided by the total number of samples tested. The percentages were calculated based on the data in (A). (C, D) Pie charts show the pathogens detected during the period of March to May 2020 and June 2020 to February 2021. Age group represents data from 0–9 years (C) and 10 years and older (D). The number of positive samples were noted above the pie chart.
Distribution of detected pathogens by age.
| Age (year) | Adenovirus (%) | Human rhinovirus/enterovirus (%) | SARS-CoV-2 (%) | Others (%) | ||||
|---|---|---|---|---|---|---|---|---|
| 0–9 | 16 | (64.0) | 90 | (59.6) | 1 | (1.8) | 7 | (24.1) |
| 10–19 | 1 | (4.0) | 10 | (6.6) | 7 | (12.7) | 1 | (3.4) |
| 20–29 | 3 | (12.0) | 10 | (6.6) | 16 | (29.1) | 4 | (13.8) |
| 30–39 | 1 | (4.0) | 14 | (9.3) | 8 | (14.5) | 3 | (10.3) |
| 40–49 | 0 | 7 | (4.6) | 2 | (3.6) | 1 | (3.4) | |
| 50–59 | 0 | 2 | (1.3) | 2 | (3.6) | 1 | (3.4) | |
| 60–69 | 0 | 7 | (4.6) | 6 | (10.9) | 2 | (6.9) | |
| 70–79 | 2 | (8.0) | 6 | (4.0) | 5 | (9.1) | 3 | (10.3) |
| 80–89 | 2 | (8.0) | 5 | (3.3) | 5 | (9.1) | 6 | (20.7) |
| 90–99 | 0 | 0 | 2 | (3.6) | 1 | (3.4) | ||
| ≥ 100 | 0 | 0 | 1 | (1.8) | 0 | |||
|
|
|
|
|
| ||||
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.